期刊
JOURNAL OF BIOLOGICAL CHEMISTRY
卷 281, 期 5, 页码 2441-2450出版社
AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
DOI: 10.1074/jbc.M511173200
关键词
-
资金
- NCI NIH HHS [CA097022] Funding Source: Medline
- NIGMS NIH HHS [GM068487] Funding Source: Medline
The BCR-ABL oncogene is the hallmark of chronic myeloid leukemia, a clonal hematopoietic stem cell disorder. BCR-ABL displays constitutive tyrosine kinase activity, required for its transformation ability. Although the molecular mechanisms behind this malignancy are not fully understood, a role for phosphatidylinositol ( PI) 3-kinase has been repeatedly described. Here we report the specific up-regulation of the class I-B catalytic subunit of PI3-kinase (p110 gamma) in response to BCR-ABL expression. We demonstrate that this upregulation is due to increased transcription and is dependent on both PI3-kinase and MEK activity. We performed in vitro kinase activity assays and show that BCR-ABL also leads to increased p110 gamma activity and that this activation requires both G protein-coupled receptor and Ras signaling. In addition, by transfection of cells with dominant negative p110 gamma, we determined that this specific PI 3-kinase isoform is involved in both proliferation and the apoptosis resistance associated with chronic myeloid leukemia. The data presented here define for the first time the ability of BCR-ABL to alter the expression levels of PI3-kinase isoforms and also demonstrate a previously unreported link between BCR-ABL and p110 gamma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据